SCHEMBL4686294

SCHEMBL4686294

COCc1cnc(Br)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32667225 0.79 MEN1 (0.32)
SCHEMBL6864414 0.78
SCHEMBL9051664 0.78
SCHEMBL26111413 0.77
Ammonia Solution, Strong SCHEMBL29207984 0.77 MEN1 (0.40)
SCHEMBL7263481 0.77
SCHEMBL2666833 0.77
SCHEMBL27935793 0.77 SLC6A3 (0.45)
SCHEMBL20093101 0.76 TLR7 (0.38)
SCHEMBL861151 0.75 L3MBTL1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 US disclosed
EP-4554938-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 EP disclosed
CN-119894879-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-25 CN disclosed
US-20240276957-A1 METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS AGIOS PHARMACEUTICALS, INC. 2024-08-22 US disclosed
CN-117964547-A Urea compound and application thereof as Sigma2 and 5HT2A dual-target inhibitor 瀚远医药有限公司 2024-05-03 CN disclosed
WO-2024067304-A1 COMPOUND WITH INHIBITORY ACTIVITY AGAINST SIGMA2 AND 5HT2A AND USE 瀚远医药有限公司 2024-04-04 WO disclosed
WO-2024015497-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2024-01-18 WO disclosed
US-20230002408-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2023-01-05 US disclosed
CN-110964023-B Fused tetracyclic compounds and application thereof in medicines 广东东阳光药业有限公司 2022-12-27 CN disclosed
EP-4077305-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS Janssen Pharmaceutica NV (BE) 2022-10-26 EP disclosed
CN-103261194-A Oxazolyl-methyl ether derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD 2013-08-21 CN disclosed
WO-2012077049-A1 OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2012-06-14 WO disclosed
EP-1554274-B1 1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS GLAXO GROUP LTD (GB) 2008-12-24 EP disclosed
US-7304087-B2 1-acyl-pyrrolidine derivatives for the treatment of viral infections GLAXO GROUP LIMITED (GB) 2007-12-04 US disclosed
US-7304087-B2 1-acyl-pyrrolidine derivatives for the treatment of viral infections GLAXO GROUP LIMITED (GB) 2007-12-04 US disclosed
US-7304087-B2 1-acyl-pyrrolidine derivatives for the treatment of viral infections GLAXO GROUP LIMITED (GB) 2007-12-04 US disclosed
US-20060258720-A1 1-Acyl-pyrrolidine derivatives for the treatment of viral infections GLAXO GROUP LIMITED (GB) 2006-11-16 US disclosed
CN-1732165-A 1-acyl-pyrrolidine derivatives for the treatment of viral infections GLAXO GROUP LTD (GB) 2006-02-08 CN disclosed
EP-1554274-A1 1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2005-07-20 EP disclosed
WO-2004037818-A1 1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2004-05-06 WO disclosed